These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
617 related items for PubMed ID: 18554462
1. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia]. Ye QD, Gu LJ, Tang JY, Xue HL, Chen J, Pan C, Chen J, Dong L, Zhou M, Jiang LM. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462 [Abstract] [Full Text] [Related]
2. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia]. Jiang H, Gu LJ, Xue HL, Tang JY, Chen J, Pan C, Chen J, Xu C, Dong L, Zhou M. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450 [Abstract] [Full Text] [Related]
3. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood. Mussolin L, Pillon M, Conter V, Piglione M, Lo Nigro L, Pierani P, Micalizzi C, Buffardi S, Basso G, Zanesco L, Rosolen A. J Clin Oncol; 2007 Nov 20; 25(33):5254-61. PubMed ID: 18024872 [Abstract] [Full Text] [Related]
4. [Prognostic value of minimal residual disease in childhood B-cell acute lymphoblastic leukemia]. Tie LJ, Gu LJ, Chen J, Jiang LM, Dong L, Pan C, Ye H, Song DL, Xue HL, Tang JY, Wang YP, Chen J. Zhonghua Xue Ye Xue Za Zhi; 2006 Feb 20; 27(2):120-3. PubMed ID: 16732969 [Abstract] [Full Text] [Related]
5. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia]. Tie LJ, Gu LJ, Song DL, Jiang LM, Xue HL, Tang JY, Dong L, Pan C, Chen J, Ye H, Wang YP, Chen J. Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 20; 26(1):6-9. PubMed ID: 15946500 [Abstract] [Full Text] [Related]
7. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China. Tie LJ, Gu LJ, Song DL, Jiang LM, Xue HL, Tang JY, Dong L, Pan C, Chen J, Ye H, Chen J. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan 20; 11(1):5-9. PubMed ID: 19149913 [Abstract] [Full Text] [Related]
8. [Evaluation on protocol SCMS-ALL-2005 for childhood B lineage acute lymphoblastic leukemia]. Tang JY, Xue HL, Chen J, Pan C, Li BS, Gu LJ, Dong L, Hu WT, Shen SH, Zhou M, Ye QD, Jiang H, Luo CY. Zhonghua Yi Xue Za Zhi; 2012 Feb 28; 92(8):546-50. PubMed ID: 22490159 [Abstract] [Full Text] [Related]
9. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA. J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891 [Abstract] [Full Text] [Related]
10. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD, Australian and New Zealand Children's Oncology Group. Br J Haematol; 2009 Aug 20; 146(3):292-9. PubMed ID: 19500099 [Abstract] [Full Text] [Related]
11. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Madzo J, Zuna J, Muzíková K, Kalinová M, Krejcí O, Hrusák O, Otová B, Starý J, Trka J. Cancer; 2003 Jan 01; 97(1):105-13. PubMed ID: 12491511 [Abstract] [Full Text] [Related]
13. Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia. Wang YR, Jin RM, Xu JW, Xiao Y, Zhou DF, Zhang ZQ. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb 01; 10(1):1-4. PubMed ID: 18289459 [Abstract] [Full Text] [Related]
14. [Clinical significance of sequential monitoring minimal residual disease in childhood B-cell acute lymphoblastic leukemia]. Wang L, Jiang H, Li H, Shao JB, Lu ZH, Yang JW, Yang WQ. Zhonghua Xue Ye Xue Za Zhi; 2011 Jun 01; 32(6):400-3. PubMed ID: 21781499 [Abstract] [Full Text] [Related]
15. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G. J Clin Oncol; 2009 Nov 01; 27(31):5168-74. PubMed ID: 19805690 [Abstract] [Full Text] [Related]
16. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group. J Clin Oncol; 2009 Jan 20; 27(3):377-84. PubMed ID: 19064980 [Abstract] [Full Text] [Related]
17. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements. Gameiro P, Mortuza FY, Hoffbrand AV, Foroni L. Haematologica; 2002 Nov 20; 87(11):1126-34. PubMed ID: 12414341 [Abstract] [Full Text] [Related]